The use of BMP-2 coupled - Nanosilver-PLGA composite grafts to induce bone repair in grossly infected segmental defects

Biomaterials

Volumn 31, Issue 35, 2010, Pages 9293-9300

  Zheng, Zhong ^a   Yin, Wei ^b,c   Zara, Janette N ^d   Li, Weiming ^b,e   Kwak, Jinny ^b   Mamidi, Rachna ^b   Lee, Min ^d   Siu, Ronald K ^b,d   Ngo, Richard ^f   Wang, Joyce ^g   Carpenter, Doug ^h   Zhang, Xinli ^b   Wu, Benjamin ^b,d   Ting, Kang ^b   Soo, Chia ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d University of California   (United States)

^e HARBIN MEDICAL UNIVERSITY   (China)

^f University at Buffalo ^*  (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h QuantumSphere Inc   (United States)

Author keywords

Antimicrobial; Bone morphogenetic protein 2 (BMP 2); Bone repair; Nanosilver particle

Indexed keywords

ALKALINE PHOSPHATASE ACTIVITY; ANTIBACTERIAL PROPERTIES; ANTIMICROBIAL; BACTERIAL COLONIES; BACTERIAL RESISTANCE; BONE DEFECT; BONE MORPHOGENETIC PROTEIN 2 (BMP-2); BONE MORPHOGENETIC PROTEIN-2; BONE REGENERATION; BONE REPAIR; CONTROL GRAFTS; IN-VITRO; INFECTED WOUNDS; MC3T3-E1; NANO SILVER; OSTEOINDUCTIVITY; POLY(LACTIC-CO-GLYCOLIC ACID);

BACTERIOLOGY; DEFECTS; MICROORGANISMS; PHOSPHATASES; PROTEINS; REPAIR;

BONE;

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; POLYGLACTIN; SILVER NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM COLONY; BONE REMODELING; CELL ADHESION; CELL PROLIFERATION; COMPOSITE GRAFT; CONTROLLED STUDY; CYTOTOXICITY; FRACTURE HEALING; MALE; MINERALIZATION; MOUSE; NONHUMAN; OSTEOBLAST; PARTICLE SIZE; PRIORITY JOURNAL; RAT; WOUND INFECTION;

ANIMALS; ANTI-INFECTIVE AGENTS; BONE MORPHOGENETIC PROTEIN 2; BONE REGENERATION; CELL LINE; CELL PROLIFERATION; IMMUNOHISTOCHEMISTRY; LACTIC ACID; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; NANOCOMPOSITES; NANOTECHNOLOGY; POLYGLYCOLIC ACID; PROSTHESES AND IMPLANTS; RATS; RATS, SPRAGUE-DAWLEY; SILVER; WOUND HEALING; X-RAY MICROTOMOGRAPHY;

BACTERIA (MICROORGANISMS);

EID: 77957971104     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.08.041     Document Type: Article

References (55)

1. Farooq A.H., Dabke H.V., Majeed M.A., Carbarns N.J., Mackie I.G. Clostridial wound infection following reconstruction of the anterior cruciate ligament using bone-patella-bone autograft. J Coll Physicians Surg Pak 2007, 17:369-370.
2. Journeaux S.F., Johnson N., Bryce S.L., Friedman S.J., Sommerville S.M., Morgan D.A. Bacterial contamination rates during bone allograft retrieval. J Arthroplasty 1999, 14:677-681.
3. Bruce J.N., Bruce S.S. Preservation of bone flaps in patients with postcraniotomy infections. J Neurosurg 2003, 98:1203-1207.
4. Mader J.T., Shirtliff M.E., Bergquist S.C., Calhoun J. Antimicrobial treatment of chronic osteomyelitis. Clin Orthop Relat Res 1999, 360:47-65.
5. Lane J.M., Tomin E., Bostrom M.P. Biosynthetic bone grafting. Clin Orthop Relat Res 1999, 367:S107-S117.
6. Arrington E.D., Smith W.J., Chambers H.G., Bucknell A.L., Davino N.A. Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res 1996, 329:300-309.
7. Damien C.J., Parsons J.R. Bone graft and bone graft substitutes: a review of current technology and applications. J Appl Biomater 1991, 2:187-208.
8. Yu D., Li Q., Mu X., Chang T., Xiong Z. Bone regeneration of critical calvarial defect in goat model by PLGA/TCP/rhBMP-2 scaffolds prepared by low-temperature rapid-prototyping technology. Int J Oral Maxillofac Surg 2008, 37:929-934.
9. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21:2475-2490.
10. Putney S.D., Burke P.A. Improving protein therapeutics with sustained-release formulations. Nat Biotechnol 1998, 16:153-157.
11. Kang Q., Sun M.H., Cheng H., Peng Y., Montag A.G., Deyrup A.T., et al. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 2004, 11:1312-1320.
12. Govender S., Csimma C., Genant H.K., Valentin-Opran A., Amit Y., Arbel R., et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002, 84:2123-2134.
13. Van de Belt H., Neut D., Schenk W., van Horn J.R., van der Mei H.C., Busscher H.J. Infection of orthopedic implants and the use of antibiotic-loaded bone cements. A review. Acta Orthop Scand 2001, 72:557-571.
14. Ovington L.G. The truth about silver. Ostomy Wound Manage 2004, 50:1S-10S.
15. Kilgus D.J., Howe D.J., Strang A. Results of periprosthetic hip and knee infections caused by resistant bacteria. Clin Orthop Relat Res 2002, 404:116-124.
16. Josefsson G., Kolmert L. Prophylaxis with systematic antibiotics versus gentamicin bone cement in total hip arthroplasty. A ten-year survey of 1,688 hips. Clin Orthop Relat Res 1993, 292:210-214.
17. Hirakawa K., Stulberg B.N., Wilde A.H., Bauer T.W., Secic M. Results of 2-stage reimplantation for infected total knee arthroplasty. J Arthroplasty 1998, 13:22-28.
18. James P.J., Butcher I.A., Gardner E.R., Hamblen D.L. Methicillin-resistant Staphylococcus epidermidis in infection of hip arthroplasties. J Bone Joint Surg Br 1994, 76:725-727.
19. Hope P.G., Kristinsson K.G., Norman P., Elson R.A. Deep infection of cemented total hip arthroplasties caused by coagulase-negative staphylococci. J Bone Joint Surg Br 1989, 71:851-855.
20. Alt V., Bechert T., Steinrucke P., Wagener M., Seidel P., Dingeldein E., et al. An in vitro assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement. Biomaterials 2004, 25:4383-4391.
21. Lok C.N., Ho C.M., Chen R., He Q.Y., Yu W.Y., Sun H., et al. Silver nanoparticles: partial oxidation and antibacterial activities. J Biol Inorg Chem 2007, 12:527-534.
22. Martinez-Castanon G.A., Nino-Martinez N., Martinez-Gutierrez F., Martinez-Mendoza J.R., Ruiz F. Synthesis and antibacterial activity of silver nanoparticles with different sizes. J Nanopart Res 2008, 10:1343-1348.
23. Leaper D.J. Silver dressings: their role in wound management. Int Wound J 2006, 3:282-294.
24. Seymour C. Audit of catheter-associated UTI using silver alloy-coated foley catheters. Br J Nurs 2006, 15:598-603.
25. Hardes J., Ahrens H., Gebert C., Streitbuerger A., Buerger H., Erren M., et al. Lack of toxicological side-effects in silver-coated megaprostheses in humans. Biomaterials 2007, 28:2869-2875.
26. Tamura K. Some effects of weak direct current and silver ions on experimental osteomyelitis and their clinical application. Nippon Seikeigeka Gakkai Zasshi 1983, 57:187-197.
27. Webster D.A., Spadaro J.A., Becker R.O., Kramer S. Silver anode treatment of chronic osteomyelitis. Clin Orthop Relat Res 1981, 161:105-114.
28. Nand S., Sengar G.K., Jain V.K., Gupta T.D. Dual use of silver for management of chronic bone infections and infected non-unions. J Indian Med Assoc 1996, 94:91-95.
29. Schreurs W.J., Rosenberg H. Effect of silver ions on transport and retention of phosphate by Escherichia coli. J Bacteriol 1982, 152:7-13.
30. Silver S., Phung le T., Silver G. Silver as biocides in burn and wound dressings and bacterial resistance to silver compounds. J Ind Microbiol Biotechnol 2006, 33:627-634.
31. Zheng Z., Deng Y., Lin X.S., Zhang L.X., Chen G.Q. Induced production of rabbit articular cartilage-derived chondrocyte collagen II on polyhydroxyalkanoate blends. J Biomat Sci-Polym E 2003, 14:615-624.
32. Deng Y., Lin X.S., Zheng Z., Deng J.G., Chen J.C., Ma H., et al. Poly(hydroxybutyrate-co-hydroxyhexanoate) promoted production of extracellular matrix of articular cartilage chondrocytes in vitro. Biomaterials 2003, 24:4273-4281.
33. Lee M., Li W.M., Siu R.K., Whang J., Zhang X.L., Soo C., et al. Biomimetic apatite-coated alginate/chitosan microparticles as osteogenic protein carriers. Biomaterials 2009, 30:6094-6101.
34. Bechert T., Steinrucke P., Guggenbichler J.P. A new method for screening anti-infective biomaterials. Nat Med 2000, 6:1053-1056.
35. Evangelista M.B., Hsiong S.X., Fernandes R., Sampaio P., Kong H.J., Barrias C.C., et al. Upregulation of bone cell differentiation through immobilization within a synthetic extracellular matrix. Biomaterials 2007, 28:3644-3655.
36. Gough J.E., Jones J.R., Hench L.L. Nodule formation and mineralisation of human primary osteoblasts cultured on a porous bioactive glass scaffold. Biomaterials 2004, 25:2039-2046.
37. Muller R., Ruegsegger P. Micro-tomographic imaging for the nondestructive evaluation of trabecular bone architecture. Stud Health Technol Inform 1997, 40:61-79.
38. Gauthier O., Muller R., von Stechow D., Lamy B., Weiss P., Bouler J.M., et al. In vivo bone regeneration with injectable calcium phosphate biomaterial: a three-dimensional micro-computed tomographic, biomechanical and SEM study. Biomaterials 2005, 26:5444-5453.
39. Foot N.C. The Masson trichrome staining methods in routine laboratory use. Stain Technol 1933, 8:101-110.
40. Taylor R.D. Modification of Brown and Brenn gram stain for differential staining of gram-positive and gram-negative bacteria in tissue sections. Am J Clin Pathol 1966, 46:472.
41. Bobryshev Y.V., Killingsworth M.C., Lord R.S.A. Spatial distribution of osteoblast-specific transcription factor Cbfa1 and bone formation in atherosclerotic arteries. Cell Tissue Res 2008, 333:225-235.
42. Kasai R., Bianco P., Robey P.G., Kahn A.J. Production and characterization of an antibody against the human bone gla protein (Bgp/Osteocalcin) propeptide and its use in immunocytochemistry of bone-cells. Bone Miner 1994, 25:167-182.
43. Jonsson P., Lindberg M., Haraldsson I., Wadstrom T. Virulence of Staphylococcus aureus in a mouse mastitis model - studies of alpha-hemolysin, coagulase, and protein-A as possible virulence determinants with protoplast fusion and gene cloning. Infect Immun 1985, 49:765-769.
44. Peschel A., Jack R.W., Otto M., Collins L.V., Staubitz P., Nicholson G., et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 2001, 193:1067-1076.
45. Gupta A., Phung L.T., Taylor D.E., Silver S. Diversity of silver resistance genes in IncH incompatibility group plasmids. Microbiology 2001, 147:3393-3402.
46. Vik H., Andersen K.J., Julshamn K., Todnem K. Neuropathy caused by silver absorption from arthroplasty cement. Lancet 1985, 1:872.
47. Sudmann E., Vik H., Rait M., Todnem K., Andersen K.J., Julsham K., et al. Systemic and local silver accumulation after total hip replacement using silver-impregnated bone cement. Med Prog Technol 1994, 20:179-184.
48. 3 on 3T3 mouse fibroblasts cell line. Acta Pol Pharm 2007, 64:175-178.
49. Jeong S.H., Yeo S.Y., Yi S.C. The effect of filler particle size on the antibacterial properties of compounded polymer/silver fibers. J Mater Sci 2005, 40:5407-5411.
50. Jeong S.H., Hwang Y.H., Yi S.C. Antibacterial properties of padded PP/PE nonwovens incorporating nano-sized silver colloids. J Mater Sci 2005, 40:5413-5418.
51. Thiel J., Pakstis L., Buzby S., Raffi M., Ni C., Pochan D.J., et al. Antibacterial properties of silver-doped titania. Small 2007, 3:799-803.
52. Martinez-Gutierrez F., Olive P.L., Banuelos A., Orrantia E., Nino N., Sanchez E.M., et al. Synthesis, characterization, and evaluation of antimicrobial and cytotoxic effect of silver and titanium nanoparticles. Nanomedicine: Nanotechnol Biol Med 2010, [Epub ahead of print].
53. Panacek A., Kvitek L., Prucek R., Kolar M., Vecerova R., Pizurova N., et al. Silver colloid nanoparticles: synthesis, characterization, and their antibacterial activity. J Phys Chem B 2006, 110:16248-16253.
54. Ellington J.K., Harris M., Webb L., Smith B., Smith T., Tan K., et al. Intracellular Staphylococcus aureus. A mechanism for the indolence of osteomyelitis. J Bone Jt Surg Br 2003, 85:918-921.
55. Calandra T., Cohen J., Infect I.S.F.D. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005, 33:1538-1548.